PTC Therapeutics (PTCT) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US69366J2006
PTC Therapeutics Inc. (NASDAQ: PTCT) is a biopharmaceutical company that specializes in developing and delivering treatments for individuals with rare disorders. The company's robust portfolio pipeline consists of a range of commercial products and product candidates at different developmental stages, including clinical, pre-clinical, and research and discovery phases.
PTC Therapeutics focuses on developing therapies for a variety of therapeutic areas, particularly in the realm of rare diseases. The company offers Translarna and Emflaza for Duchenne muscular dystrophy treatment in specific regions, while also providing Tegsedi, Waylivra, and Evrysdi for rare disease treatment in various markets, including Latin America and Brazil.
Beyond its existing treatments, PTC Therapeutics is actively pursuing the development of cutting-edge therapies through its splicing, bio-e, metabolic, gene therapy, and oncology platforms. The company collaborates with industry leaders like F. Hoffman-La Roche Ltd, Spinal Muscular Atrophy Foundation, and Akcea Therapeutics, Inc. to drive drug discovery and research in regenerative medicine.
Founded in 1998 and headquartered in South Plainfield, New Jersey, PTC Therapeutics Inc.'s mission is to bring life-changing therapies to patients with unmet medical needs. To learn more about the company, visit their website at https://www.ptcbio.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
PTCT Stock Overview
Market Cap in USD | 1,931m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2013-06-20 |
PTCT Stock Ratings
Growth 5y | -2.25 |
Fundamental | -56.0 |
Dividend | - |
Rel. Performance vs Sector | -5.88 |
Analysts | 3.14/5 |
Fair Price Momentum | 36.49 USD |
Fair Price DCF | - |
PTCT Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
PTCT Growth Ratios
Growth 12m | -40.67% |
Growth Correlation 12m | -35% |
Growth Correlation 3m | 10% |
CAGR 5y | -4.04% |
Sharpe Ratio 12m | -0.67 |
Alpha vs SP500 12m | -65.88 |
Beta vs SP500 5y weekly | 0.92 |
ValueRay RSI | 92.63 |
Volatility GJR Garch 1y | 83.07% |
Price / SMA 50 | 14.01% |
Price / SMA 200 | 15.65% |
Current Volume | 468.7k |
Average Volume 20d | 1040.5k |
External Links for PTCT Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of May 07, 2024, the stock is trading at USD 32.96 with a total of 468,720 shares traded.
Over the past week, the price has changed by +2.55%, over one month by +21.98%, over three months by +23.03% and over the past year by -40.95%.
According to ValueRays Forecast Model, PTCT PTC Therapeutics will be worth about 39.8 in May 2025. The stock is currently trading at 32.96. This means that the stock has a potential upside of +20.63%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 27.9 | -15.3 |
Analysts Target Price | 35.4 | 7.46 |
ValueRay Target Price | 39.8 | 20.6 |